Spinal cord injury is defined as damage to any part of the spinal cord or nerves at the end of the spinal canal, often resulting in permanent changes in strength, sensation and other body functions below the site of the injury. Traumatic spinal cord injury (TSCI) is classified as injury to the spine caused by a traumatic event.
This report provides the current prevalent population for TSCI across 15 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Turkey, Canada, Netherlands, Australia, South Africa and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains an overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of TSCI have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for TSCI include:
• Deep Vein Thromboses (DVT)
• Urinary Tract Infections (UTI)
• Pressure sores
• Neuropathic pain
• Spasticity
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global TSCI’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of TSCI and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on TSCI’s prevalent population.
• Identify sub-populations within TSCI which require treatment.
• Gain an understanding of the specific markets that have the largest number of TSCI patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions/Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Prevalence for Traumatic Spinal Cord Injury
o TSCI by Cause
o Location of TSCI
o Level of Impairment of TSCI
o Sequelae of TSCI
• Abbreviations used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables
• ASIA grading classification for spinal cord injury
• Frankel scale for classification for spinal cord injury
• Glasgow Coma Scale for scoring patient response
• Prevalence of TSCI, total (000s)
• Prevalence of TSCI, males (000s)
• Prevalence of TSCI, females (000s)
• Cause of TSCI, total (000s)
• TSCI patients by location of injury, total (000s)
• TSCI patients by ASIA score, total (000s)
• TSCI patients with paraplegia, total (000s)
• TSCI patients with tetraplegia, total (000s)
• TSCI patients with DVT, total (000s)
• TSCI patients with UTIs, total (000s)
• TSCI patients with Pressure Sores, total (000s)
• TSCI patients with Spasticity, total (000s)
• TSCI patients with Neuropathic pain, total (000s)
• Abbreviations and Acronyms used in the report
• USA Prevalence of TSCI by 5-yr age cohort, males (000s)
• USA Prevalence of TSCI by 5-yr age cohort, females (000s)
• France Prevalence of TSCI by 5-yr age cohort, males (000s)
• France Prevalence of TSCI by 5-yr age cohort, females (000s)
• Germany Prevalence of TSCI by 5-yr age cohort, males (000s)
• Germany Prevalence of TSCI by 5-yr age cohort, females (000s)
• Italy Prevalence of TSCI by 5-yr age cohort, males (000s)
• Italy Prevalence of TSCI by 5-yr age cohort, females (000s)
• Spain Prevalence of TSCI by 5-yr age cohort, males (000s)
• Spain Prevalence of TSCI by 5-yr age cohort, females (000s)
• United Kingdom Prevalence of TSCI by 5-yr age cohort, males (000s)
• United Kingdom Prevalence of TSCI by 5-yr age cohort, females (000s)
• Netherlands Prevalence of TSCI by 5-yr age cohort, males (000s)
• Netherlands Prevalence of TSCI by 5-yr age cohort, females (000s)
• Turkey Prevalence of TSCI by 5-yr age cohort, males (000s)
• Turkey Prevalence of TSCI by 5-yr age cohort, females (000s)
• Canada Prevalence of TSCI by 5-yr age cohort, males (000s)
• Canada Prevalence of TSCI by 5-yr age cohort, females (000s)
• Australia Prevalence of TSCI by 5-yr age cohort, males (000s)
• Australia Prevalence of TSCI by 5-yr age cohort, females (000s)
• South Africa Prevalence of TSCI by 5-yr age cohort, males (000s)
• South Africa Prevalence of TSCI by 5-yr age cohort, females (000s)
• Brazil Prevalence of TSCI by 5-yr age cohort, males (000s)
• Brazil Prevalence of TSCI by 5-yr age cohort, females (000s)
• Japan Prevalence of TSCI by 5-yr age cohort, males (000s)
• Japan Prevalence of TSCI by 5-yr age cohort, females (000s)
• India Prevalence of TSCI by 5-yr age cohort, males (000s)
• India Prevalence of TSCI by 5-yr age cohort, females (000s)
• China Prevalence of TSCI by 5-yr age cohort, males (000s)
• China Prevalence of TSCI by 5-yr age cohort, females (000s)
